JRoon, You clearly don't understand the ruling in GSK v Teva. First explain how there is no overlap between the two Vascepa indications. If you can't, explain how that overlap wouldn't invalidate all generic "skinny labels". Sleven,
Jruin, what is your response to North’s view that FDA will pull the ANDA label from every generic that is enjoying now on the ground Amarin HTG patents were fraudulently invalidated?
Market Data 
Markets 
AI
